ClinicalTrials.gov
ClinicalTrials.gov Menu

An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cells Transduced With Placebo or an Anti- Human Immunodeficiency Virus Type 1 (HIV-1) Ribozyme (OZ1) in Participants With HIV-1 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00074997
Recruitment Status : Completed
First Posted : December 31, 2003
Last Update Posted : June 20, 2016
Sponsor:
Information provided by (Responsible Party):
Janssen-Cilag Pty Ltd